← Browse by Condition
Medical Condition
small cell lung cancer
Total Trials
11
Recruiting Now
11
Trial Phases
Phase 1, Phase 2, Phase 2, Phase 1
Cancer clinical trials represent the largest single category of recruiting studies worldwide, encompassing everything from early-phase safety studies of novel oncology drugs to large Phase 3 comparisons against current standard-of-care chemotherapy regimens. The field has accelerated dramatically with the rise of immunotherapy, targeted therapies, and CAR-T cell treatments that have transformed outcomes for previously untreatable malignancies.
Trials include checkpoint inhibitors (PD-1/PD-L1 agents), KRAS inhibitors, ADC (antibody-drug conjugates), combination chemotherapy regimens, radiation protocols, and surgical technique comparisons. Many trials stratify by biomarker status (PD-L1 expression, TMB, MSI-H) to identify patients most likely to benefit.
The NCI, pharmaceutical sponsors, and academic cancer centers collectively fund thousands of oncology trials annually across every cancer type.
Frequently Asked Questions — small cell lung cancer Clinical Trials
How many clinical trials are currently recruiting for small cell lung cancer?
ClinicalMetric currently tracks 11 actively recruiting clinical trials for small cell lung cancer, sourced in real time from ClinicalTrials.gov. The total number of registered studies—including those not yet enrolling or in active follow-up—is 11. Trial availability changes daily as new studies open enrollment and existing ones reach capacity.
What trial phases are available for small cell lung cancer?
small cell lung cancer research spans Phase 1 (4 trials), Phase 2 (5 trials), Phase 3 (1 trial). Phase 1 studies evaluate safety and dosing in small groups, Phase 2 studies assess preliminary efficacy in 100–300 participants, and Phase 3 trials compare the new treatment against the standard of care in 300–3,000+ patients. Phase 4 post-approval studies monitor long-term outcomes in real-world populations.
How do I find out if I qualify for a small cell lung cancer clinical trial?
Eligibility criteria for small cell lung cancer trials vary by study and typically specify age range, disease stage or severity, prior treatment history, and specific diagnostic or laboratory parameters. Each listing on ClinicalMetric links to the full protocol on ClinicalTrials.gov, where inclusion and exclusion criteria are documented. Contact the sponsoring site's research coordinator directly to confirm your eligibility—your treating physician or specialist can also help identify the most appropriate trial based on your medical history and current treatment status.
Trial Phases
Phase 1 4
Phase 2 5
Phase 3 1
Top Sponsors
1 trial
1 trial
1 trial
1 trial
1 trial
Recruiting Clinical Trials
NCT04342429
Recruiting
Prospective Study of Intensity-Modulated Proton Therapy (IMPT) for Small Cell Lung Cancer
Enrollment
30 pts
Location
United States
Sponsor
Emory University
NCT04585750 Phase 1, Phase 2
Recruiting
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
Enrollment
300 pts
Location
United States, Austr...
Sponsor
PMV Pharmaceuticals, Inc
NCT05797493
Recruiting
Panomic Approach to Immune-Connected Assays in Small Cell Lung Cancer
Enrollment
100 pts
Location
Italy
Sponsor
Fondazione Policlinico Univers...
NCT07174583 Phase 1, Phase 2
Recruiting
A Study of IDE849 in Patients With DLL3 Expressing Tumors Including Small Cell Lung Cancer
Enrollment
208 pts
Location
United States, Austr...
Sponsor
IDEAYA Biosciences
NCT04539977 Phase 2
Recruiting
PD-L1 Antibody (TQB2450) Plus Chemotherapy for Previously Untreated Limited- Stage Small-cell Lung Cancer
Enrollment
40 pts
Location
China
Sponsor
Shanghai Pulmonary Hospital, S...
NCT02146170
Recruiting
Tissue Procurement and Natural History Study of People With Non-Small Cell Lung Cancer, Small Cell Lung Cancer, Extrapulmonary Small Cell Cancer, Pulmonary Neuroendocrine Tumors, and Thymic Epithelial Tumors
Enrollment
2,000 pts
Location
United States
Sponsor
National Cancer Institute (NCI...
NCT06295926 Phase 2
Recruiting
Serplulimab Combined With CCRT for LS-SCLC.
Enrollment
96 pts
Location
China
Sponsor
Peking Union Medical College H...
NCT06505824 Phase 1
Recruiting
A Study of BL-M14D1 in Patients With Locally Advanced or Metastatic Small Cell Lung Cancer, Neuroendocrine Tumors and Other Solid Tumors
Enrollment
22 pts
Location
China
Sponsor
Sichuan Baili Pharmaceutical C...
NCT07010263 Phase 3
Recruiting
A Study of AK112 as Consolidation Treatment for Patients With Limited Stage Small-cell Lung Cancer Who Have Not Progressed Following Concurrent Chemoradiation Therapy
Enrollment
560 pts
Location
China
Sponsor
Akeso
NCT06255197
Recruiting
Characteristics, Treatment Patterns and Outcomes for Patients With Surgically Resected Lung Cancers
Enrollment
60,000 pts
Location
China
Sponsor
Cancer Institute and Hospital,...
NCT03093688 Phase 1, Phase 2
Recruiting
Clinical Safty and Efficacy Study of Infusion of iNKT Cells and CD8+T Cells in Patients With Advanced Solid Tumor
Enrollment
40 pts
Location
China
Sponsor
Shanghai Public Health Clinica...
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer · Last Reviewed: April 2026 · Data Methodology